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A culture of BALB/c 3T3 cells grown in the presence of 40 PM of the ceramide analog compound RV538 (2-decanoyl- 
amino-3-morpholino-I-phenylpropanol) for several passages caused a substantial decrease in the level of all glyco- 
sphingolipids and an accumulation of ceramide and sphingomyelin. Associated with these chemical changes of sphingo- 
lipid composition and metabolism, the following phenotypic changes were observed: (i) loss of the cobblestone appear- 
ance at cell density saturation and development of fibroblastic appearance with partial overlapping of cells; (ii) reduction 
of cell growth rate; (iii) enhanced production of lactic acid; (iv) enhanced rate of glucose transport; and (v) higher inci- 
dence of large colony formation with infiltrating appearance in soft agar. Cell morphology changes, lactate pruduction, 
and enhanced sugar uptake were reversed by co-culturing cells with gangliosides, particularly trisialogangliosides. Thus. 
these phenotypic changes mimicking those of oncogenically transformed cells are closely related to the blocked synthesis 
of glycolipids in these cells, whereas other changes may be caused by an accumulation of ceramide and sphingomyelin. 
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1. INTRODUCTION 
RV538 
Glycosphingolipids in cell membranes have been 
implicated as regulators of cell growth and 
mediators of cell social interaction [ 11. As a test of 
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Fig.1. The structure of 2-decanoylamino-3-morpholino-l- 
phenylpropanol (compound RV538) and ceramide. The 
compound was crystallized as the hydrochloride (Mr 427). 
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this concept, we tried to inhibit synthesis of total 
glycolipids by application of a ceramide analog, 
compounds RV538 (2-decanoylamino-3-morpho- 
lino-1-phenylpropanol, fig.l), which inhibits 
UDP-glucose : ceramide glucosyltransferase [2]. 
Culturing 3T3 cells in the presence of RV538 
resulted in a reduced growth rate, but caused 
remarkable changes of cellular phenotypes imilar 
to those observed in oncogenically transformed 
cells, i.e., changes in morphology, enhanced pro- 
duction of lactic acid, changes in cell growth 
behavior in soft agar, and enhanced sugar trans- 
port. These RV538-induced phenotypic changes 
are reported in this paper. 
2. MATERIALS AND METHODS 
All glycolipids were prepared in this laboratory. The 
ceramide analog RV538 was synthesized as previously described 
[2]. [‘H]Galactose and [‘Hlpalmitic acid were from New 
England Nuclear (Boston, MA). Sphingomyelin and Oil Red 0 
were from Sigma (St. Louis, MO). Ceramide was prepared by 
Smith degradation of cerebroside [3]. Conditions of cell growth 
in the absence or presence of RV538, and the monitoring of 
sphingolipid biosynthesis are described in the legend of fig.2. 
Levels of lactic acid and pyruvic acid in the medium were deter- 
mined by spectrometry of NAD reduction as described 
previously [4], using a Sigma kit (Sigma). Glucose transport was 
determined as described by Christopher et al. [5]. Conditions 
for culturing cells for the determination of lactic acid and sugar 
transport are described in the footnote of table 1. Cell growth 
behavior in soft agar was determined as described in the legend 
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Fig.2. Sphingolipids of control and RV538-treated 3T3 cells. Subconfluent cell cultures grown in DME with 10% FCS were 
continuously cultured in a new medium containing 3 pCi [3H]Gal/ml in the presence or absence of 40pM of RV538 for 24 h. 
Glycolipids extracted from lo6 cells were purified as acetate, placed in each lane after deacetylation, and developed in 
chloroform/methanol/water (60: 35 : 8, v/v). Bands corresponding to each glycolipid were scraped and radioactivities were counted 
(panel I). Each number represents the mean value of three separate experiments. TLC patterns are shown in panel II. Panels show 
the autoradiogram (A), orcinol staining (B), and resorcinol staining (C) of the plate. (a) Control 3T3 cells; (b) RV538-treated 3T3 cells. 
Cells cultured in the presence or absence of 40 pM RV538 for 10 passages were metabolically labeled with 10 ,Ki [3H]palmitic acid/ml 
for 12 h in the presence or absence of RV538. Extracted cells were Folch partitioned, and the lower phase was washed 5 times with 
theoretical upper phase. Aliquots of washed lower phase were placed on an HPTLC plate (Merck, Darmstadt, FRG) with ceramide 
or sphingomyelin standard, developed, and visualized by Dittmer-Lester’s spray and hypochlorite-benzidine as described in section 2. 
The bands corresponding to standard lipids were scraped and counted in a liquid scintillation counter (panel III). Values represent 
means of three separate experiments. 
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Fig.3. Changes in growth behavior of 3T3 cells induced by 
RV538 in soft agar or on cell culture plates. (Panel I) Cells 
cultured in DME with 10% FCS without (A) or with (B) 40 pM 
RV538 for 10 passages. Cells were trypsinized and suspended in 
0.3% agar and overlaid on solid 0.5% agar. Pictures were taken 
12 days after plating. (Panel II) Control or RV538-treated cells 
supplemented after attachment with: (A) no additives (control); 
(B) 50pg CT/ml; (C) 40 FM RV538; (D) CT plus RV538. 
Pictures of confluent cells were taken after several days. 
I 
of fig.3. Glycolipids were separated as acetates [6] and analyzed 
on HPTLC plates. Ceramide was separated from glycolipids 
and sphingomyelin in dichloroethane/methanol/water 
(90:20:0.5, v/v), and sphingomyelin was separated from other 
phospholipids in isopropanol/water (7 : 3, v/v). Sphingolipids 
on TLC were visualized by hypochlorite-benzidine [7], and 
sphingomyelin and other phospholipids were detected by Ditt- 
mer and Lester’s spray reagent (81. 
3. RESULTS 
3.1. R V538-induced changes in sphingolipid 
synthesis and cell morphology 
The quantities and pattern of biosynthesis of 
sphingolipids were greatly reduced in 3T3 cells 
cultured in the presence of 40pM RV538 for five 
passages, while accumulation of sphingomyelin 
and ceramide was greatly increased (fig.2, panels I 
and III). Associated with these major changes in 
sphingolipid synthesis, the typical cobblestone ap- 
pearance of the saturated cell population of 
BALB/c 3T3 cells was lost, although the cell 
saturation density was reduced from 2.4 f 0.2 x 
105/cm2 to 1.7 t 0.05 x 105/cm2. 
Table 1 
Effect of RV538 and CT on lactic acid production and glucose uptake in BALB/c 3T3 cells 
Untreated RV538 
treated 
RV538 and CT 
treated 
CT 
treated 
Lactic acid produceda 
(nmol/lO’ cells per h) 
Glucose uptakeb 
(cpm x 10e4/mg protein 
per 10 min) 
35.3 f 5.6 91.4 * 7.7 44.7 + 1.3 35.0 ? 5.2 
(0.6 + 0.1) (0.3 + 0.1) 
8.9 * 0.1 13.5 * 0.5 11.0 + 0.1 4.8 + 0.1 
a Cells were cultured for 10 passages in DME containing 10% FCS and 40pM RV538, and 
subcultured in new medium in the presence or absence of 40 pM RV538 and/or 50 pg CT per ml. 
After confluency (6 h), the medium was collected and deproteinated with 8% perchloric acid, and 
lactic acid content was determined by spectrophotometry. Pyruvic acid was essentially absent in the 
medium (values in parentheses) 
’ Cells cultured as described above were plated in 35 mm dishes and continuously cultured in the 
presence or absence of RV538 and/or CT. Adherent cells were incubated for 10 min in DME 
without glucose or FCS, but containing [‘Hldeoxyglucose (2 pCi/pg deoxyglucose per ml). After 
washing with DME without glucose or FCS, cells were solubilized in 0.1 N NaOH/O. 1% SDS, and 
radioactivity and protein content were determined 
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3.2. Anomalous phenotypic characteristics of 4. DISCUSSION 
R V538-treated cells 
3T3 cells cultured in a medium containing 
RV538 displayed various characteristic phenotypic 
changes: (i) enhanced production of lactic acid, 
causing the culture medium to become acidic; (ii) 
enhanced transport of [3H]deoxyglucose (table 1); 
(iii) anomalous growth in soft agar, i.e. a larger 
number of colonies with increasing number of cells 
and an infiltrating diffuse boundary (fig.3); and 
(iv) accumulation of anomalous perinuclear 
granules (stained intensely by Oil Red 0), which 
became obvious after 4-5 passages in the presence 
of RV538. Control cells grown in a medium 
without RV538 did not display these phenotypic 
changes, and phenotypes of altered cells reverted 
to normal when RV538 was removed from the 
culture medium. 
Although glycolipid alteration associated with 
differentiation, development, and oncogenesis has 
been well established [l], a major question remains 
as to whether the alteration is the cause or the 
result of phenotypic changes. To answer this ques- 
tion, glycolipids were added to the culture media in 
various studies [9- 121. Another useful approach is 
the inhibition of glycolipid synthesis by com- 
petitive substrate inhibitors and observation of any 
changes in cell phenotype; however, this approach 
has not been well developed. Vunnam and Radin 
[2] synthesized analogs of ceramides that inhibit 
the activity of UDP-Glc : ceramide glucosyltrans- 
ferase, the enzyme that initiates synthesis of essen- 
tially all glycosphingolipids except galactosyl- 
ceramide and derived analogs. The present study 
shows that in 3T3 cells cultured in the presence of 
one such analog, RV538 (fig.l), production of all 
glycolipids (including GlcCer, LacCer, GM3, GM2, 
GMI, and GD1,) is greatly reduced. Treated cells, 
however, accumulate several-fold more sphingo- 
myelin and ceramide than do untreated cells. Thus, 
the synthetic pathway of sphingolipids in treated 
cells is diverted from the glycosphingolipid to the 
sphingomyelin pathway. 
3.3. Reversible effect of ganglioside on 
R V538-treated cells 
When 3T3 cells were co-cultured in the presence 
of RV538 and trisialoganglioside (GT), cell mor- 
phology returned to the cobblestone appearance 
(fig.3), concentration of lactic acid decreased 
significantly with increasing GT ganglioside con- 
centration (fig.4), and glucose uptake was reduced 
(see table 1). 
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Fig.4. Inhibitory effect of GT on RV538-induced lactic acid 
production. 3T3 cells were cultured in the presence (0) or 
absence (0) of 40gM RV538 with various amounts of GT, as 
indicated on the abscissa. After confluency, the medium was 
changed to one with or without RV538 and/or GT, collected 
6 h later, and used for determination of lactic acid. 
Associated with such dramatic changes in 
sphingolipid synthesis induced by RV538, various 
phenotypic changes (e.g., reduced growth rate, 
morphological changes, enhanced glucose trans- 
port, enhanced lactic acid production, changes in 
soft agar growth behavior, and appearance of 
perinuclear lipophilic granules) have been ob- 
served. However, it is not clear from the present 
study which changes are caused by reduction of 
glycolipid synthesis and which are related to ac- 
cumulation of ceramide and sphingomyelin. 
Accumulation of perinuclear lipophilic granules 
may coincide with accumulation of sphingomyelin 
and ceramide. Interestingly, Lipsky and Pagan0 
[13] observed accumulation of a fluorescent 
ceramide analog (N-[7-(4-nitrobenzo-2-oxa-1,3- 
diazole)]aminocaproyl-sphingosine in mitochon- 
drial membranes added exogenously to fibroblasts. 
It is possible that enhanced lactic acid production 
could reflect impaired oxidative phosphorylation 
in mitochondria due to accumulation of ceramide 
in the mitochondrial membrane. Further study is 
necessary to clarify the possible role of ceramide 
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and sphingomyelin in mitochondrial function. 
Reduction of cell growth may result from low effi- 
ciency of ATP production caused by impaired 
mitochondrial function. On the other hand, loss of 
the cobblestone appearance and other morpho- 
logical changes may be related to reduction of 
glycolipid synthesis, although a definite functional 
correlation remains to be established. 
Interestingly, co-culturing of cells with various 
gangliosides, particularly GT, was observed to 
reverse the phenotypic changes caused by RV538, 
e.g., it caused reduction in lactic acid production 
and sugar transport, and reversion of mor- 
phological changes. These observations suggest 
that these phenotypic changes are partially related 
to the reduction of ganglioside levels, and that ap- 
proaches involving the modification of 
sphingolipid metabolism by ceramide analog may 
offer a useful tool for studies of sphingolipid func- 
tion in general. 
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